Results 101 to 110 of about 3,783 (170)

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

Kidney Blood Press Res
Macciò L, Russo E, Costigliolo F, Battaglia Y, Viazzi F, Esposito P.   +5 more
europepmc   +1 more source

Multi-omics analyses demonstrate complement dysregulation is involved in focal segmental glomerulosclerosis. [PDF]

Front Immunol
Xu Y, Chen S, Zhang Y, Li Y, Li G.
europepmc   +1 more source

The Role of Complement Anaphylatoxins (C3a and C5a) in Non-small Cell Lung Cancer: A Systematic Review. [PDF]

Cureus
Skarentzos K, Karagialani DK, Mitros V, Economopoulou P, Foukas P.   +4 more
europepmc   +1 more source

Effect of Decay-accelerating Factor on LPS-induced Acute Lung Injury in the Rat. [PDF]

In Vivo
Detsika MG, Nikitopoulou I, Orfanos SE, Dimopoulou I, Kotanidou A.   +4 more
europepmc   +1 more source

Complement C5a/C5aR1 pathway facilitates glioblastoma progression via fostering glioma stem cell-macrophage symbiosis. [PDF]

J Neuroinflammation
Zhu H, Cheng L, Liu D, Ma Y, Fan H, He S, Liang W, Mei D, Ma X, Li R, Mi H, Wang J, Li J, Yu X, Zhang S, Shu K.   +15 more
europepmc   +1 more source

High throughput mutational characterization of the GPCR ligand C5a using yeast display and deep sequencing. [PDF]

Structure
Xu Y, Thakkar K, Guan L, Miao Y, Mehibel M, Lee RB, Marciano D, Viswanathan V, Wang Z, Wang J, Ji L, Cao H, Petrakian CF, Valenzuela J, LaGory E, Jia X, Moon EJ, Martinez R, Wu F, Frock RL, Moding EJ, Le QT, Rankin EB, Zhang C, Huang P, Olcina MM, Giaccia AJ, Graves EE.   +27 more
europepmc   +1 more source

Complement C5a Promotes Epithelial-Mesenchymal Transition in Pterygium via C5aR Activation. [PDF]

Invest Ophthalmol Vis Sci
Han J, Gong Q, Wang H, Xie B, Ye L, Shen L, Hu L.   +6 more
europepmc   +1 more source

The free fatty acid 2 receptor regulates C5a induced neutrophil superoxide production and its sensitivity to inhibition by the antagonist avacopan. [PDF]

Front Immunol
Khan Z, Levin NK, Dahlgren C, Sundqvist M, Khan F, Forsman H, Björkman L.   +6 more
europepmc   +1 more source

Targeting C5AR1 disrupts complement-driven G0-phase maintenance and overcomes metabolic drug resistance in glioma. [PDF]

J Transl Med
Qian Y, Zhao K.
europepmc   +1 more source

Complement dysregulation during the early phases of synucleinopathy. [PDF]

Acta Neuropathol
Khan H, Gifford M, Kordbacheh A, Bury A, Panoushek S, Cole-Strauss A, Kemp CJ, Luk KC, Steece-Collier K, Kuhn NC, Kanaan NM, Sortwell CE, Patterson JR, Benskey MJ.   +13 more
europepmc   +1 more source